<?xml version="1.0" encoding="UTF-8"?>
<p>Acute phase serum samples (median 4 days post onset of symptoms) from 92 Lao patients (
 <bold>
  <xref rid="pone.0230337.t001" ref-type="table">Table 1</xref>
 </bold>) with a PCR-confirmed DENV infection were analyzed using the SD Bioline Dengue Duo rapid test (
 <bold>
  <xref ref-type="fig" rid="pone.0230337.g001">Fig 1</xref>
 </bold>). Overall, 53/92 samples (57.6%) generated a positive result in the NS1 antigen rapid test. NS1 positivity strongly correlated with high viral load (indicated by low Ct-values) and significantly decreased from 79.2% for samples collected between day 1 and day 3 post onset of symptoms to 33.3% between day 6 and 11 (
 <bold>
  <xref ref-type="fig" rid="pone.0230337.g001">Fig 1A</xref>
 </bold>). DENV-specific IgM antibodies were detected in 21/92 samples (22.8%) with the highest percentage (44.4%) of positivity found in the samples collected later than day 5 after onset of symptoms (
 <bold>
  <xref ref-type="fig" rid="pone.0230337.g001">Fig 1B</xref>
 </bold>). In 44.6% of all samples (41/92), DENV-specific IgG antibodies were detected (
 <bold>
  <xref ref-type="fig" rid="pone.0230337.g001">Fig 1C</xref>
 </bold>) indicating a high incidence of secondary DENV infections. Overall, 68.5% of samples tested positive in the NS1 and/or the IgM test (
 <bold>
  <xref ref-type="fig" rid="pone.0230337.g001">Fig 1D</xref>
 </bold>). Similar observations were made when analyzing samples from a smaller collective (n = 26) of DF patients with a PCR-confirmed DENV infection collected 2014 in an endemic region in South America (Valledupar/Colombia [
 <xref rid="pone.0230337.ref013" ref-type="bibr">13</xref>â€“
 <xref rid="pone.0230337.ref015" ref-type="bibr">15</xref>]) (
 <bold>
  <xref ref-type="supplementary-material" rid="pone.0230337.s002">S1 Fig</xref>
 </bold>).
</p>
